Home › Funds › Paradigm Biocapital Advisors LP › INSM
Paradigm Biocapital Advisors LP position in INSM
INSMED INC · Health Care
Paradigm Biocapital Advisors LP reported holding 2,695,977 shares of INSM (INSMED INC) in its Q3 2026 13F filing — a position valued at US$307.7M, representing 6.12% of its reported portfolio and ranking #5 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed INSM holdings in 4 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's INSM position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in INSM in Q1 2025 at 451,359 shares (US$34.4M). The position peaked in Q3 2026 at 2,695,977 shares, worth US$307.7M. Across 4 filings, Paradigm Biocapital Advisors LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,695,977 shares valued at US$307.7M — an increase of 1,370,000 shares quarter over quarter.. Notable position changes include a 103% increase in Q3 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 451.36K | $34.43M | New |
| Q1 2026 | 1.25M | $205.13M | New |
| Q2 2026 | 1.33M | $141.38M | Add |
| Q3 2026 | 2.70M | $307.72M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INSM and 13F data
INSM (INSMED INC) is a Health Care company. 41 other funds we track also report a position in INSM — the largest reported positions include BAKER BROS. ADVISORS LP (US$937.8M), Orbis Allan Gray Ltd (US$768.6M), Darwin Global Management, Ltd. (US$673.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INSM
- BAKER BROS. ADVISORS LP 8.80M sh · $937.84M · Q2 2026
- Orbis Allan Gray Ltd 6.73M sh · $768.62M · Q3 2026
- Darwin Global Management, Ltd. 6.43M sh · $673.60M · Q2 2026
- Artisan Partners Limited Partnership 5.58M sh · $636.68M · Q3 2026
- D. E. Shaw & Co 5.94M sh · $633.12M · Q2 2026
- RTW INVESTMENTS, LP 3.10M sh · $353.44M · Q3 2026
- Maverick Capital 2.15M sh · $229.31M · Q2 2026
- MAVERICK CAPITAL LTD 2.15M sh · $229.31M · Q2 2026
- Polar Capital Holdings Plc 1.75M sh · $200.17M · Q3 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 1.55M sh · $177.20M · Q3 2026
- Deep Track Capital, LP 1.35M sh · $154.09M · Q3 2026
- Bellevue Group AG 1.39M sh · $148.57M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held INSM?
Paradigm Biocapital Advisors LP has disclosed INSM holdings in 4 of the last 7 reported quarters, going back to Q1 2025.
What is Paradigm Biocapital Advisors LP's current position in INSM?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 2.70M shares of INSM (INSMED INC), valued at $307.72M, representing 6.12% of its reported portfolio and ranking #5.
Has Paradigm Biocapital Advisors LP been buying or selling INSM?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in INSM. The position peaked in Q3 2026 at 2.70M shares.
Which other funds hold INSM?
Other major institutional holders of INSM include BAKER BROS. ADVISORS LP, Orbis Allan Gray Ltd, Darwin Global Management, Ltd., among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.